Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nanotherapy for Duchenne muscular dystrophy.

Michael E Nance1, Chady H Hakim1,2, N Nora Yang2

  • 1Department of Microbiology and Immunology, University of Missouri School of Medicine, Columbia, MO, USA.

Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology
|April 12, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deaths in gene therapy of Duchenne muscular dystrophy and other diseases: Underlying mechanisms and mitigating strategies.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Canine Model of Duchenne Muscular Dystrophy.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

DWORF expression is reduced in a large animal model of Duchenne muscular dystrophy.

Disease models & mechanisms·2025
Same author

Circulatory CCL2 distinguishes Duchenne muscular dystrophy dogs.

Disease models & mechanisms·2025
Same author

[High mobility group protein B1(HMGB1) promotes myeloid dendritic cell maturation and increases Th17 cell/Treg cell ratio in patients with immune primary thrombocytopenia].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology·2025
Same author

Adeno-Associated Virus 8 and 9 Myofibre Type/Size Tropism Profiling Reveals Therapeutic Effect of Microdystrophin in Canines.

Journal of cachexia, sarcopenia and muscle·2025

Nanobiotechnology offers promising treatments for Duchenne muscular dystrophy (DMD) by targeting the dystrophin gene. Challenges remain in gene size and bodywide delivery for effective DMD nanotherapy.

Area of Science:

  • Nanomedicine and Nanobiotechnology
  • Molecular Therapy
  • Genetic Disorders

Background:

  • Duchenne muscular dystrophy (DMD) is a fatal X-linked genetic disorder characterized by progressive muscle wasting due to mutations in the dystrophin gene.
  • Current therapeutic strategies for DMD are limited, highlighting the need for innovative treatment approaches.

Purpose of the Study:

  • To review the potential of nanobiotechnology-based therapies for Duchenne muscular dystrophy.
  • To discuss the challenges and future directions in developing nanotherapies for DMD.

Main Methods:

  • Review of preclinical and clinical advancements in nanomedicine for DMD.
  • Analysis of regulatory approvals for DMD treatments and their implications for nanotherapy.
  • Exploration of novel nano-delivery systems and gene-editing techniques.

Related Experiment Videos

Main Results:

  • Nanobiotechnology, including viral and nonviral nanoparticles, shows promise for dystrophin gene repair in DMD.
  • Several nanotherapies, such as adeno-associated virus (AAV)-mediated gene therapy, are progressing to clinical trials.
  • Recent drug approvals provide insights into translating DMD nanotherapy to human patients.

Conclusions:

  • Despite significant progress, challenges like the large dystrophin gene size and efficient bodywide muscle targeting persist.
  • Innovations in miniature gene design, engineered AAV capsids, and nanoparticle-mediated exon-skipping are crucial for future breakthroughs.
  • Nanobiotechnology holds substantial potential to revolutionize DMD treatment by addressing the underlying genetic defect and improving therapeutic delivery.